融资方面，汇宇制药当日融资买入482.31万元。当前融资余额2.64亿元，占流通市值的4.25%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，汇宇制药12月23日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.02万股，融券余额18.43万元，超过近一年90%分位水平，处于高位。 12月23日，汇宇制药跌1.47%，成交额4670.30万元。两融数据显示，当日汇宇制药获融资买入额482.31 万元，融资偿还460.88万元，融资净买入21.44万元。截至12月23日，汇宇制药融资融券余额合计2.64亿 元。 责任编辑：小浪快报 分红方面，汇宇制药A股上市后累计派现4.74亿元。近三年，累计派现3.85亿元。 机构持仓方面，截止2025年9月30日，汇宇制药十大流通股东中，平安医疗健康混合A（003032）位居 第七大流通股东，持股683.78万股，为新进股东。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、 ...

Core Viewpoint - Huyou Pharmaceutical experienced a decline of 5.03% in stock price, currently trading at 21.16 CNY per share, with a total market capitalization of 8.963 billion CNY [1] Company Overview - Sichuan Huyou Pharmaceutical Co., Ltd. was established on October 12, 2010, and went public on October 26, 2021. The company specializes in the research, production, and sales of drugs in the oncology field and complex injectable drugs [1] - The main revenue composition of the company includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Fund Holdings - Huyou Pharmaceutical is a significant holding in the Hongde Medical Innovation Mixed Fund A (012481), which held 50,000 shares, accounting for 6.13% of the fund's net value, ranking as the ninth largest holding [2] - The fund has reported a year-to-date return of 48.5% and a one-year return of 44.18%, with a total fund size of 14.8031 million CNY [2] - The fund manager, Cao Zhaoxu, has a tenure of 4 years and 306 days, with the fund's best and worst returns during his management being -1.98% and -35.88%, respectively [2]

Core Viewpoint - Huayu Pharmaceutical's stock increased by 5.03% on October 31, reaching 21.30 CNY per share, with a total market capitalization of 9.023 billion CNY [1] Company Overview - Sichuan Huayu Pharmaceutical Co., Ltd. was established on October 12, 2010, and listed on October 26, 2021. The company focuses on the research, production, and sales of drugs in the oncology field and complex injectable drugs [1] - The main revenue composition includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Shareholder Information - Ping An Fund's Ping An Medical Health Mixed A (003032) entered the top ten circulating shareholders of Huayu Pharmaceutical in the third quarter, holding 6.8378 million shares, which is 1.99% of the circulating shares [2] - The estimated floating profit from this investment is approximately 6.9746 million CNY [2] Fund Performance - Ping An Medical Health Mixed A (003032) was established on November 24, 2017, with a current size of 2.028 billion CNY. The fund has achieved a year-to-date return of 56.7%, ranking 794 out of 8154 in its category [2] - Over the past year, the fund's return is 47.82%, ranking 1222 out of 8046, and since inception, it has returned 143.53% [2]

Core Insights - On October 9, Huayu Pharmaceutical experienced a decline of 0.61% with a trading volume of 74.55 million yuan [1] - The company reported a financing buy-in of 10.62 million yuan and a net financing buy of 2.07 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Huayu Pharmaceutical was 213 million yuan, representing 2.90% of its circulating market value [1] Financing Summary - On October 9, Huayu Pharmaceutical had a financing buy-in of 10.62 million yuan, with a current financing balance of 213 million yuan, which is above the 80th percentile of the past year [1] - The company had no short selling activity on October 9, with a short selling balance of 0.00 yuan, indicating a high level of short selling availability [1] Company Performance - As of June 30, Huayu Pharmaceutical had 16,300 shareholders, a decrease of 11.81% from the previous period, while the average circulating shares per person increased by 25.85% to 21,131 shares [2] - For the first half of 2025, the company reported a revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net profit attributable to shareholders of -80.72 million yuan, a significant decline of 223.78% [2] - Since its A-share listing, Huayu Pharmaceutical has distributed a total of 474 million yuan in dividends, with 385 million yuan distributed over the past three years [2]

Core Insights - On September 19, Huayu Pharmaceutical experienced a decline of 5.06%, with a stock price of 24.41 CNY per share, a trading volume of 146 million CNY, a turnover rate of 1.69%, and a total market capitalization of 10.34 billion CNY [1] Company Overview - Sichuan Huayu Pharmaceutical Co., Ltd. is located at 333 Hanyang Road, Shizhong District, Neijiang City, Sichuan Province, and was established on October 12, 2010, with its listing date on October 26, 2021 [1] - The company's main business involves the research, development, production, and domestic and international sales of drugs in the oncology field and complex injectable drugs [1] - The revenue composition of the main business includes: 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Fund Holdings - From the perspective of major fund holdings, one fund under Dacheng Fund has a significant position in Huayu Pharmaceutical [2] - Dacheng Medical Health Stock A (012045) held 431,500 shares in the second quarter, accounting for 4.07% of the fund's net value, ranking as the tenth largest holding [2] - The fund has experienced a floating loss of approximately 560,900 CNY today [2] Fund Performance - Dacheng Medical Health Stock A (012045) was established on September 16, 2021, with a latest scale of 153 million CNY [2] - Year-to-date return is 36.96%, ranking 1224 out of 4222 in its category; the one-year return is 52.07%, ranking 1953 out of 3805; since inception, it has a loss of 22.93% [2] - The fund manager, Yang Ting, has a tenure of 11 years and 89 days, with total assets under management of 1.281 billion CNY, achieving a best return of 77.63% and a worst return of -24.45% during his tenure [2]

Group 1 - The core viewpoint of the news is that Huayu Pharmaceutical has experienced fluctuations in financing activities, with a notable net financing outflow on September 15, indicating potential investor caution [1] - On September 15, Huayu Pharmaceutical's stock price increased by 0.84%, with a trading volume of 187 million yuan, while the financing buy-in amount was 25.51 million yuan and the financing repayment was 35.92 million yuan, resulting in a net financing outflow of 10.41 million yuan [1] - As of September 15, the total balance of margin trading for Huayu Pharmaceutical was 208 million yuan, which represents 2.65% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Huayu Pharmaceutical was 16,300, a decrease of 11.81% from the previous period, while the average circulating shares per person increased by 25.85% to 21,131 shares [2] - For the first half of 2025, Huayu Pharmaceutical reported a revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net profit attributable to shareholders of -80.72 million yuan, reflecting a significant year-on-year decline of 223.78% [2] - Since its A-share listing, Huayu Pharmaceutical has distributed a total of 474 million yuan in dividends, with 385 million yuan distributed over the past three years [2]